April 24, 2018 / 6:17 AM / in a month

BRIEF-Biomed Lublin Adopts Strategy For 2018-2022

April 24 (Reuters) - BIOMED LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA:

* ADOPTS STRATEGY 2018-2022

* PLANS TO INVEST IN CONSTRUCTION OF NEW PRODUCTION PLANT

* IDENTIFIES THREE STRATEGIC PRODUCTS: ONKO BCG, ANTI-TUBERCULOSIS VACCINE BCG AND DISTREPTAZA

* CONSTRUCTION OF NEW PRODUCTION PLANT WILL ALLOW TO INCREASE PRODUCTION VOLUME OF STRATEGIC PRODUCTS

* SEES YEARLY REVENUE EXCEEDING 100 MILLION ZLOTYS AFTER IMPLEMENTATION OF STRATEGIC PLANS

* ESTIMATES INVESTMENT COSTS AT ABOUT 150 MILLION ZLOTYS, PLANS TO GET 60% OF FINANCING FROM EU SUBSIDIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below